The consequences extend beyond slowed weight loss
The Takeaway While both Novo and Lilly have multi-year regulatory head-starts and are now rapidly becoming part of the zeitgeist around treating obesity, Regenerons angle of addressing muscle loss could help set it apart from other GLP-1 hopefuls and even incumbents by leading to improved long-term outcomes.
"My self-preservation kicked in I respect the medical profession, and I can certainly see the risks." She said it was "concerning but not hugely surprising" that the vial contained nearly double the retatrutide than what the label advertised
In the coming years, patients and providers will have the options of newly launched biosimilars, novel GLP-1s, combination drugs, and approvals for allied indications
Today were discussing whether or not these medications help achieve and maintain weight loss
For many of my patients with obesity and sleep apnea, sustained weight loss means better breathing at night, lower blood pressure, fewer medications and more energy
